Clinical Trial Update: Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating the efficacy of omega-3 fatty acids in individuals with first-episode schizophrenia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Medical University of Lodz | Conditions: Schizophrenia | Phase 4 | Status: UNKNOWN